Radiographic evaluation of advanced non-small cell lung cancer by RECIST

SHEN Yiyi; ZHU Xiaoyun; SHAN Fei; XING Wei

doi:10.19732/j.cnki.2096-6212.2018.06.017

您当前的位置：

首页 >

文章列表页 >

Radiographic evaluation of advanced non-small cell lung cancer by RECIST

更新时间：2025-12-15

- Radiographic evaluation of advanced non-small cell lung cancer by RECIST
- Vol. 27, Issue 6, Pages: 509-514(2018)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.19732/j.cnki.2096-6212.2018.06.017
  CLC：
- Published Online：16 January 2019，
  
  Published：16 January 2019
- 稿件说明：
移动端阅览
沈亦亦,朱小云,单飞,等. 进展期非小细胞肺癌疗效的RECIST影像学评估[J]. 肿瘤影像学, 2018, 27(6): 509-514 https://doi.

org/10.19732/j.cnki.2096-6212.2018.06.017
沈亦亦,朱小云,单飞,等. 进展期非小细胞肺癌疗效的RECIST影像学评估[J]. 肿瘤影像学, 2018, 27(6): 509-514 https://doi. DOI： 10.19732/j.cnki.2096-6212.2018.06.017.

org/10.19732/j.cnki.2096-6212.2018.06.017 DOI：

摘要

进展期非小细胞肺癌（non-small cell lung cancer，NSCLC）疗效评估常采用基于影像学的实体瘤疗效评价标准（response evaluation criteria in solid tumors，RECIST）。随着肿瘤靶向治疗等新治疗方案的临床应用，很有必要深入了解现行及修订的RECIST影像学评估指标与内容，做到扬长避短、有的放矢。本文就RECIST在NSCLC疗效评估中的进展予以综述。

Abstract

Response Evaluation Criteria in Solid Tumors (RECIST) based on medical imaging is usually utilized to assess the treatment response of advanced non-small cell lung cancer (NSCLC). With the introduction of new treatments (e.g. targeted therapy) in clinic

a deep insight of the evaluation indices and contents in the current and revised RECIST is necessary to well understand the strengths and weaknesses of RECIST in evaluation of NSCLC. The present paper reviews the advances in response evaluation of NSCLC using RECIST.

关键词

Keywords

references

Views

2524

下载量

CNKI被引量

Alert me when the article has been cited

提交

Tools

Publicity Resources

No data

Related Author

No data

Related Institution

No data

AI问答

⁰